Episode #9 focuses on Heated Intraperitoneal Chemotherapy (HIPEC) treatment. For those that may be unfamiliar with the topic, HIPEC is a highly concentrated and heated type of chemo directed at the abdomen during surgery. HIPEC differs from more traditional and systemic treatments due to the delivery of drugs into a patient's body. The chemo does not circulate through the entire body during HIPEC. It only delivers directly to the cancerous cells.
Subscribe to the podcast on SoundCloud to get alerts when each new episode is posted.
In the second part of our discussion on colorectal cancer trials, Dr. James Fleshman joins Ron to discuss the ACOSOG Z6051 Randomized Clinical Trial. This surgical trial aims to decipher the differences of open versus laparoscopic surgery in the treatment of colorectal cancer. To read more about Dr. Fleshman's findings and reports click here.
Dr. Fleshman is the Helen and Stanley Joseph Seeger Professor and Chairman, Department of Surgery at Baylor University Medical Center in Dallas. His professional focus is the treatment of patients with colorectal diseases. He has developed an international reputation in the laparoscopic treatment of colorectal cancer and the development of randomized controlled trials to evaluate the use of laparoscopic techniques in the treatment of colorectal cancer. Click here to read a full bio.
In this episode, Jeff and Ron also answer a listener question and discuss the future of patient trials in this field.
The How We Treat Colon & Rectal Cancer podcast's next two episodes will feature discussions about clinical trials focused on colorectal cancer treatment. In part one, Dr. Deborah Schrag joins us to provide an inside look at the PROSPECT trial currently taking place.
PROSPECT is the acronym for Preoperative Radiation Or Selective Preoperative Radiation and Evaluation before Chemotherapy and Total Mesorectal Excision (TME). From the on-going trial, Dr. Schrag and her team hope to decipher and compare the results of standard chemo and radiation treatment using a regimen of drugs named FOLFOX (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin). To learn more about this trial, listeners can click here.
Episode #5 is now available on SoundCloud and iTunes. In this episode, our hosts talk over a case with two specialists in immunotherapy from the Dana-Farber: Dr. Osama Rahma and Dr. Matthew Yurgelun. After reviewing the patient and case details, our guests outline the unique set of challenges during treatment due to the patient testing positive for Lynch Syndrome. It is an engaging discussion.
Post your questions and comments here or email email@example.com.
Stay tuned for Episode #5 later this month. The discussion topic will be "Immunotherapy." Tweet @RonaldBledayMD or comment on this post with your questions/comments. Ron and Jeff will answer them in the upcoming episode.
Stay tuned for another podcast episode coming soon.
The How We Treat Colon and Rectal Cancer Podcast's fourth episode will focus on a recent case involving complications due to a patient's age and frailty. The medical experts joining us will be Dr. Nadine Jackson McCleary and Dr. John Saltzman.
To get email alerts when a new episode is posted, subscribe to this blog using the form in the left hand menu of this site.